Ar sail foesegol credaf ei bod yn bwysig darparu Truvada® pan fo’n briodol yn glinigol. Wrth reswm, mae’n rhaid inni sicrhau bod ein hadnoddau yn cael eu targedu yn effeithiol. Dylai’r astudiaeth helpu mynd i’r afael â’r ansicrwydd a nodwyd gan AWMSG o ran cyfraddau nifer achosion HIV yng Nghymru, o ran unigolion yn cadw at y drefn drin ac effaith hyn oll ar leihau’r cyfraddau heintio.
On ethical grounds I believe it is important to make Truvada® available where clinically appropriate. We must of course ensure our resources are targeted to best effect. The study should help to address the areas of uncertainty identified by AWMSG concerning the incidence rates of HIV infection in Wales, the issues around individuals adhering to the medication regime and the impact of this on the reduction of infection rates.